ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 22 of 50
Up
УЖМБС 2021, 6(1): 145–152
https://doi.org/10.26693/jmbs06.01.145
Clinical Medicine

Prognostic Value of Asymmetric Dimethylarginine in the Development of Complications in the Hospital Period of Acute Myocardial Infarction with ST-Segment Elevation in Patients with Type 2 Diabetes Mellitus

Feldman D. А. 1, Ryndina N. G. 1, Kravchun P. G. 1, Krayz I.G. 2, Zabashta V.F. 3
Abstract

The purpose of the study was to determine the prognostic value of asymmetric dimethylarginine in the development of complications in the hospital period of acute myocardial infarction with ST segment elevation in patients with type 2 diabetes mellitus. Material and methods. The study design consisted of 120 patients. They were divided into 2 groups. Group 1 consisted of patients with acute myocardial infarction and concomitant type 2 diabetes mellitus (n=70), group 2 included patients with acute myocardial infarction without concomitant type 2 diabetes mellitus (n=50). Patients of both groups matched on age and sex (60 men (50%) and 60 women (50%); their average age was 66.35±0.91 years, р<0.05). The control group consisted of 20 almost healthy people, among them 12 women (60%) and 8 men (40%) (average age was 45.17±2.88 years). The patients were divided into 3 tertiles according to the level of аsymmetric dimethylarginine (ADMA): ADMA ⩽1.45 μmol/l – 1st tertile; 1.45 μmol/l< ADMA ⩽1.98 μmol/l - 2nd tertile; ADMA >1.98 μmol/l - 3rd tertile. Results and discussion. The obtained results showed that the level of ADMA in patients with acute myocardial infarction in combination with type 2 diabetes was by 2.57 times (p <0.05) higher compared to patients without concomitant type 2 diabetes. In particular, the ADMA level was at 1.57±0.11 μmol/l in patients with acute myocardial infarction in combination with concomitant type 2 diabetes, while in patients with acute myocardial infarction without concomitant type 2 diabetes it was at 0.61±0.06 μmol/l. The ADMA value at >1.13 μmol/l in patients with acute myocardial infarction in combination with type 2 diabetes is a predictor of acute left ventricular failure. The ADMA tertiles were used to determine the acute myocardial infarction severity class based on the Killip scale. It is noteworthy that severer classes of acute myocardial infarction on the Killip scale were observed in a patient whose ADMA value belonged to the 3rd tertile group. We determined the ADMA value of A >2.08 μmol/l in patients with acute myocardial infarction in combination with type 2 diabetes, which was a predictor of a life-threatening condition of cardiogenic shock. Conclusion. The asymmetric dimethylarginine exhibits the following predictor properties: in relation to the development of acute left ventricular failure – at >1.13 μmol/l; in relation to the development of cardiogenic shock - at >2.08 μmol/l during the hospital period of acute myocardial infarction with ST-segment elevation in patients with concomitant type 2 diabetes. It is advisable to continue studying the marker of endothelial dysfunction (asymmetric dimethylarginine) as a predictor of adverse myocardial infarction in combination with concomitant type 2 diabetes

Keywords: asymmetric dimethylarginine, acute myocardial infarction, type 2 diabetes mellitus

Full text: PDF (Ukr) 327K

References
  1. Rodionov RN, Blokhin IO, Galagudza MM, Shlyakhta EV, Lentu SR. Assymetrychnиj dymetylargynyn y ego rol' v еtyologyy y patogeneze serdechno-sosudystyh zabolevany [Asymmetric dimethylarginine and its role in the etiology and pathogenesis of cardiovascular diseases]. Arterial hypertension. 2008; 14(4): 306-314. [Russian] https://doi.org/10.18705/1607-419X-2008-14-4-306-314
  2. Zhuravleva LV, Lopina NA. Uroven' assymetrychnogo dymetylargynyna i ego znachenye v dyagnostyke aterosklerotycheskogo porazhenyja koronarnyh sosudov [The level of asymmetric dimethylarginine and its importance in the diagnosis of atherosclerotic lesions of the coronary vessels]. Medicines of Ukraine Plus. 2016; 3(28): 45-50. [Russian]
  3. Herrera MD, Mingorance C, Rodríguez-Rodríguez R, Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Research Reviews. 2010; 9(2): 142-152. https://doi.org/10.1016/j.arr.2009.07.002
  4. Hirsch L, Shechter A, Feinberg MS, Koren-Morag N, Shechter M. The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent coronary heart disease. International journal of cardiology. 2011; 151: 342-347. https://doi.org/10.1016/j.ijcard.2010.08.069
  5. Lee R, Margaritis M, Channon KM, Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Current medicinal chemistry. 2012; 19: 2504-2520. https://doi.org/10.2174/092986712800493057
  6. Matsuzawa Y, Sugiyama S, Sumida H. Peripheral endothelial function and cardiovascular events in high-risk patients. Journal of the American Heart Association. 2013; 2: 1-21. https://doi.org/10.1161/JAHA.113.000426
  7. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. International journal of cardiology. 2013; 168: 344-351. https://doi.org/10.1016/j.ijcard.2012.09.047
  8. Reriani M, Sara JD, Flammer A, Gulati R, Li J, Rihal C. Lerman Coronary endothelial function testing provides superior discrimination compared to standard clinical risk scoring in prediction of cardiovascular events. Coronary Artery Disease. 2016; 27(3): 213-220. https://doi.org/10.1097/MCA.0000000000000347
  9. Shechter M, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L. Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. The American journal of cardiology. 2014; 113: 162-167. https://doi.org/10.1016/j.amjcard.2013.08.051
  10. Xu Y, Arora RC, Hiebert BM. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. European heart journal cardiovascular Imaging. 2014; 15: 736-746. https://doi.org/10.1093/ehjci/jet256
  11. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiology Clinics. 2014; 32(3): 439-455. https://doi.org/10.1016/j.ccl.2014.04.001
  12. Hamilton SJ, Watts GF. Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment. The Review of Diabetic Studies. 2013; 10(2-3): 133-156. https://doi.org/10.1900/RDS.2013.10.133
  13. Hong Z, Reeves KJ, Sun Z, Li Z, Brown NJ, Meininger GA. Vascular smooth muscle cell stiffness and adhesion to collagen I modified by vasoactive agonists. PLoS ONE. 2015; 10: 12. https://doi.org/10.1371/journal.pone.0119533
  14. Hong Z, Sun Z, Li M, Li Z, Bunyak F, Ersoy I. Vasoactive agonists exert dynamic and coordinated effects on vascular smooth muscle cell elasticity, cytoskeletal remodelling and adhesion. Journal of Physiology. 2014; 592(6): 1249-1266. https://doi.org/10.1113/jphysiol.2013.264929
  15. Meng L, Park J, Cai Q, Lanting L, Reddy MA, Natarajan R. Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. The American Journal of Physiology. 2010; 298(3): 736-745. https://doi.org/10.1152/ajpheart.00935.2009
  16. Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World Journal of Cardiology. 2015; 7(3): 119-124. https://doi.org/10.4330/wjc.v7.i3.119
  17. Shulkina SG, Smirnova EN, Zhelobov VG. Klynycheskoe znachenye markerov еndotelyal'noj dysfunkcyy v dyagnostyke funkcyonal'nogo sostojanyja pochek u bol'nиh s arteryal'noj gypertenzyej v sochetanyy s ozhyrenyem [Clinical significance of markers of endothelial dysfunction in the diagnosis of the functional state of the kidneys in patients with arterial hypertension combined with obesity]. Journal of scientific articles Health and education in the XXI century. 2016; 18(5): 19-24. [Russian]
  18. Gorbas IM, Smirnova IP. Еpydemyologycheskye aspektи serdechno-sosudystиh zabolevanyj [Epidemiological aspects of cardiovascular diseases]. [Russian]. Available from: https://compendium.com.ua/clinical-guidelines/cardiology/section-3/glava-1-epidemiologicheskie-aspekty-serdechno-sosudistyh-zabolevanij/ю
  19. Bolezni serdechno-sosudystoj sistemy i rak - naybolee chastye prychiny smerti sredi ukraincev v 2020 godu [Cardiovascular diseases and cancer are the most common causes of death among Ukrainians in 2020]. [Russian]. Available from: https://112.ua/zdorovie/bolezni-serdechno-sosudistoy-sistemy-i-rak-samye-chastye-prichiny-smertey-sredi-ukraincev-v-2020-godu-gosstat-547120.html
  20. Menshikova IG. Klynyka, dyagnostyka, pryncypy lechenyja s osnovamy fyzycheskoj reabylytacyy bol'nyh ostrym ynfarktom myokarda [Clinic, diagnostics, principles of treatment with the basics of physical rehabilitation of patients with acute myocardial infarction]. Blagoveshchensk; 2015. 8 p. [Russian]
  21. Oganov RG, Maslennikova GYa, Koltunov IE, Kalinina AM. Neobhodymыe uslovyja dlja profylaktyky serdechno-sosudystыh y drugyh neynfekcyonnuh zabolevanyj [Necessary conditions for the prevention of cardiovascular and other non-infectious diseases]. Cardiovascular therapy and prevention. 2010; 9(6): 4-9. [Russian]
  22. Zaklady okhorony zdorov'ya ta zakhvoryuvanist naselennya Ukrainy u 2013 rotsi. Derzhavna sluzhba statystyky Ukrainy. Statystychnyi byuleten [Health care facilities and morbidity of the population of Ukraine in 2013. State Statistics Service of Ukraine. Statistical bulletin]. K; 2014; [Ukrainian]. Available from: www.ukrstat.gov.ua
  23. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. Journal of Internal Medicine. 2007 Aug; 262(2): 145-56. https://doi.org/10.1111/j.1365-2796.2007.01831.x
  24. Booth GL, Kapral MK. Recept trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care. 2006 Jan; 29(1): 32-7. https://doi.org/10.2337/diacare.29.01.06.dc05-0776
  25. Korneva KG, Panova EI. Saharnиj dyabet 2-go typa y prognostychesky neblagopryjatnыe faktory [Type 2 diabetes mellitus and prognostically unfavorable factors]. Clinical medicine. 2010; 6: 43-47. [Russian]
  26. Alexandrov AA, Zvolinskaya EYu. Ocenka ryska razvytyja serdechno-sosudystыh zabolevanyj u lyc molodogo vozrasta [Assessment of the risk of developing cardiovascular diseases in young people]. Cardiology. 2010; 8: 37-47. [Russian]
  27. Aleksandrov AA. Profylaktyka serdechno-sosudystuh zabolevanyj s detstva: problemu, uspehy [Prevention of cardiovascular diseases from childhood: problems, successes]. Cardiovascular therapy and prevention. 2012; 11(2): 96-103. [Russian] https://doi.org/10.15829/1728-8800-2012-2-96-103
  28. Huang Y, Cai X, Mai W, Li M, Hu Y. Assiciations of prediabetes with all-course and cardiovascular mortality: A metaanalysis. Annals of Medicine. 2014; 46: 684-692. https://doi.org/10.3109/07853890.2014.955051
  29. Park KH, Park WJ. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. J Korean Med Sci. 2015 Sep; 30(9): 1213-25. https://doi.org/10.3346/jkms.2015.30.9.1213
  30. Shishkin AN, Lyndina ML. Endotelyal'naja dysfunkcyja, metabolycheskyj syndrom y mykroal'bumynuryja [Endothelial dysfunction, metabolic syndrome, and microalbuminuria]. Nephrology. 2009; 3: 24-32. [Russian]
  31. Zhuravleva LV, Lopina NA. Uroven' assymetrychnogo dymetylargynyna y ego znachenye v dyagnostyke aterosklerotycheskogo porazhenyja koronarnгh sosudov [The level of asymmetric dimethylarginine and its importance in the diagnosis of atherosclerotic lesions of the coronary vessels]. Liki Ukrainy plus. 2016; 3(28): 45-50. [Russian]
  32. Minukhina DV, Babajan VD. Dynamika rivnja asymetrychnogo dimetylargininu u hvoryh na gostryj infarkt miokarda z suputnim cukrovym diabetom 2 typu pry perkutannomu vtruchanni [Dynamics of asymmetric dimethylarginine levels in patients with acute myocardial infarction with concomitant type 2 diabetes mellitus with percutaneous intervention]. Materialy III Mizhnarodnoi naukovo-praktychnoi konferencii, 2019 Mar 14-15. 2019; p. 179. [Ukrainian]